Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2020 Sep;39(9):2803-2810.
doi: 10.1007/s10067-020-05230-0. Epub 2020 Jul 28.

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review

Affiliations
Review

Successful recovery of recurrence of positive SARS-CoV-2 RNA in COVID-19 patient with systemic lupus erythematosus: a case report and review

Feng He et al. Clin Rheumatol. 2020 Sep.

Abstract

COVID-19 has become a global concern. A large number of reports have explained the clinical characteristics and treatment strategies of COVID-19, but the characteristics and treatment of COVID-19 patient with systemic lupus erythematosus (SLE) are still unclear. Here, we report the clinical features and treatment of the first SLE patient with confirmed COVID-19 pneumonia. This was a 39-year-old woman, diagnosed with SLE 15 years ago, whose overall clinical characteristics (symptoms, laboratory tests, and chest CTs) were similar to those of the general COVID-19 patients. She continued to take the previous SLE drugs (doses of glucocorticoids, hydroxychloroquine, and immunosuppressive agents were not reduced) and was treated with strict antiviral and infection prevention treatment. After the first discharge, she got a recurrence of COVID-19 during her home isolation, and then returned to hospital and continued the previous therapy. Finally, this long-term immune suppressive patient's COVID-19 was successfully cured. The successful recovery of this case has significant reference value for the future treatment of COVID-19 patients with SLE. Key Points • COVID-19 patients with SLE is advocated to continue the medical treatment for SLE. • Hydroxychloroquine may have potential benefits for COVID-19 patients with SLE. • COVID-19 patients with SLE is prone to relapse, and multiple follow-ups are necessary.

Keywords: COVID-19; Recurrence; SARS-CoV-2; Systemic lupus erythematosus.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Timeline of disease course according to days from initial presentation of illness and days from hospital admission. + means SARS-CoV-2 RNA is positive. − means SARS-CoV-2 RNA is negative. x means chest CT is done on that day
Fig. 2
Fig. 2
High-resolution computed tomography images of twice hospital admission and twice follow-ups. a CTs after the first hospital admission, multiple ground glass density lesions were observed in the lower lobe of the bilateral lung. b CTs after the recurrence of positive SARS-CoV-2 RNA. c CTs during follow-up. The red arrows indicate the lesions

Comment in

Similar articles

  • Coronavirus disease 2019 (COVID-19) in autoimmune and inflammatory conditions: clinical characteristics of poor outcomes.
    Montero F, Martínez-Barrio J, Serrano-Benavente B, González T, Rivera J, Molina Collada J, Castrejón I, Álvaro-Gracia J. Montero F, et al. Rheumatol Int. 2020 Oct;40(10):1593-1598. doi: 10.1007/s00296-020-04676-4. Epub 2020 Aug 13. Rheumatol Int. 2020. PMID: 32794113 Free PMC article.
  • Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
    Nuño L, Novella Navarro M, Bonilla G, Franco-Gómez K, Aguado P, Peiteado D, Monjo I, Tornero C, Villalba A, Miranda-Carus ME, De Miguel E, Bogas P, Castilla-Plaza A, Bernad-Pineda M, García-Lorenzo E, Rodríguez-Araya T, Balsa A. Nuño L, et al. Ann Rheum Dis. 2020 Dec;79(12):1659-1661. doi: 10.1136/annrheumdis-2020-218054. Epub 2020 Jun 30. Ann Rheum Dis. 2020. PMID: 32606046 Free PMC article. No abstract available.
  • Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases.
    Tadolini M, Codecasa LR, García-García JM, Blanc FX, Borisov S, Alffenaar JW, Andréjak C, Bachez P, Bart PA, Belilovski E, Cardoso-Landivar J, Centis R, D'Ambrosio L, Luiza De Souza-Galvão M, Dominguez-Castellano A, Dourmane S, Fréchet Jachym M, Froissart A, Giacomet V, Goletti D, Grard S, Gualano G, Izadifar A, Le Du D, Marín Royo M, Mazza-Stalder J, Motta I, Ong CWM, Palmieri F, Rivière F, Rodrigo T, Silva DR, Sánchez-Montalvá A, Saporiti M, Scarpellini P, Schlemmer F, Spanevello A, Sumarokova E, Tabernero E, Tambyah PA, Tiberi S, Torre A, Visca D, Zabaleta Murguiondo M, Sotgiu G, Migliori GB. Tadolini M, et al. Eur Respir J. 2020 Jul 9;56(1):2001398. doi: 10.1183/13993003.01398-2020. Print 2020 Jul. Eur Respir J. 2020. PMID: 32457198 Free PMC article.
  • COVID-19 in Children: Clinical Approach and Management.
    Sankar J, Dhochak N, Kabra SK, Lodha R. Sankar J, et al. Indian J Pediatr. 2020 Jun;87(6):433-442. doi: 10.1007/s12098-020-03292-1. Epub 2020 Apr 27. Indian J Pediatr. 2020. PMID: 32338347 Free PMC article. Review.
  • A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab.
    Cai S, Sun W, Li M, Dong L. Cai S, et al. Clin Rheumatol. 2020 Sep;39(9):2797-2802. doi: 10.1007/s10067-020-05234-w. Epub 2020 Jun 19. Clin Rheumatol. 2020. PMID: 32562070 Free PMC article. Review.

Cited by

References

    1. COVID-19 cases worldwide. Available from: https://www.worldometers.info/coronavirus/. Accessed 30 Apr 2020
    1. Rahman A, Isenberg DA. Systemic lupus erythematosus. N Engl J Med. 2008;358(9):929–939. doi: 10.1056/NEJMra071297. - DOI - PubMed
    1. Miyara M, Amoura Z, Parizot C, Badoual C, Dorgham K, Trad S, Nochy D, Debré P, Piette JC, Gorochov G. Global natural regulatory T cell depletion in active systemic lupus erythematosus. J Immunol. 2005;175(12):8392–8400. doi: 10.4049/jimmunol.175.12.8392. - DOI - PubMed
    1. Yang J, Yang X, Zou H, Chu Y, Li M. Recovery of the immune balance between Th17 and regulatory T cells as a treatment for systemic lupus erythematosus. Rheumatology (Oxford) 2011;50(8):1366–1372. doi: 10.1093/rheumatology/ker116. - DOI - PubMed
    1. Katsuyama E, Suarez-Fueyo A, Bradley SJ, Mizui M, Marin AV, Mulki L et al (2020) The CD38/NAD/SIRTUIN1/EZH2 axis mitigates cytotoxic CD8 T cell function and identifies patients with SLE prone to infections. Cell Rep 30(1) - PMC - PubMed

MeSH terms